Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have spe…
Biotechnology
US, Boston [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 86.08 | 91.12 | 94.29 | 81.67 | 89.25 | 89.49 | 87.84 | 87.64 | 88.95 | 86.56 | 86.84 | 88.14 | 88.06 | 87.90 | 87.17 | |
| Profit Margin | -628.70 | -526.35 | 2.10 | -7.01 | -36.72 | -127.25 | -54.06 | -6.58 | 10.59 | 68.80 | 28.27 | 43.70 | 30.92 | 37.20 | 36.79 | |
| Operating Margin | -601.10 | -485.51 | 8.07 | 0.15 | -74.54 | -119.30 | -45.40 | 0.58 | 4.95 | 20.84 | 28.77 | 46.03 | 36.73 | 48.23 | 38.12 | |
|
EPS Growth
|
-13.15 | -1.89 | 103.71 | -457.14 | -296.00 | -58.59 | 26.43 | 80.09 | 330.44 | 678.30 | -44.49 | 127.95 | -12.93 | 42.68 | 8.33 | |
| EPS USD | -370.00 | -377.00 | 14.00 | -50.00 | -198.00 | -314.00 | -231.00 | -46.00 | 106.00 | 825.00 | 458.00 | 1,044.00 | 909.00 | 1,297.00 | 1,405.00 | |
| Return on Assets (ROA) | -32.81 | -43.74 | 1.34 | -3.88 | -19.19 | -31.61 | -22.35 | -3.87 | 7.43 | 33.57 | 14.15 | 23.07 | 17.44 | 18.30 | 15.92 | |
| Return on Equity (ROE) | -58.49 | -149.74 | 3.76 | -10.71 | -32.81 | -67.38 | -51.08 | -8.37 | 12.90 | 47.28 | 19.34 | 31.22 | 23.19 | 23.88 | 20.59 | |
| Return on Invested Capital (ROIC) | -49.26 | -68.58 | 5.61 | 0.57 | -35.08 | -35.78 | -24.70 | 0.50 | -27.38 | 44.06 | 15.10 | 26.69 | 22.30 | 23.36 | 16.85 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 9.51 | 31.12 | 27.01 | 24.87 | 19.74 | 36.70 | 36.35 | 40.01 | 16.54 | 9.24 | 7.31 | 5.31 | 4.49 | 3.09 | 3.56 | |
| Debt/Equity | 16.95 | 106.55 | 75.67 | 68.69 | 33.75 | 78.21 | 83.07 | 86.51 | 28.72 | 13.01 | 9.99 | 7.18 | 5.98 | 4.03 | 4.60 | |
| Debt/EBITDA | 53.96 | -44.37 | -33.98 | 4,387.55 | -25.44 | -32.74 | -22.37 | -2,255.32 | -353.67 | -314.09 | -173.67 | -169.59 | -223.69 | -228.83 | -243.26 | |
|
Debt/Capitalization
|
14.49 | 51.59 | 43.07 | 40.72 | 25.24 | 43.89 | 45.37 | 46.38 | 22.31 | 11.51 | 9.08 | 6.70 | 5.64 | 3.88 | 4.40 | |
| Long-Term Debt/Capitalization | 12.30 | 44.25 | 33.70 | 40.23 | 24.53 | 42.95 | 42.89 | 38.51 | 21.64 | 11.34 | 8.67 | 6.27 | 5.22 | 3.28 | 3.96 | |
| Interest Debt per Share USD | 1.15 | 2.78 | 3.08 | 3.31 | 2.14 | 3.96 | 4.12 | 5.09 | 2.59 | 2.40 | 2.59 | 2.62 | 2.58 | 2.40 | 3.31 | |
| Debt Growth | -46.49 | 249.07 | -25.51 | 68.16 | -34.45 | 87.17 | -0.57 | 2.15 | -32.73 | 0.58 | 1.80 | 0.71 | -4.26 | 0.77 | 44.10 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 196.10 | 222.64 | 158.72 | 367.43 | 399.31 | 420.40 | 267.62 | 22,139.88 | 307.62 | 517.45 | 382.67 | 501.57 | 481.15 | 521.74 | 398.72 | |
| Quick Ratio | 194.22 | 219.88 | 137.35 | 338.51 | 389.76 | 396.49 | 240.96 | 20,563.74 | 293.59 | 500.07 | 368.76 | 483.57 | 462.30 | 502.79 | 360.40 | |
| Cash Ratio | 67.01 | 51.22 | 56.67 | 113.13 | 143.10 | 169.79 | 141.16 | 14,884.90 | 206.30 | 370.40 | 258.14 | 383.83 | 362.67 | 432.16 | 292.39 | |
| Operating Cash Flow Ratio | - - | -100 | - - | - - | - - | -100 | - - | 2,900 | 100 | 100 | 100 | 200 | 100 | 100 | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | 177,525.00 | - - | 71.61 | 918.74 | 920.88 | 197.70 | 223.85 | 271.20 | 246.02 | 329.32 | 327.02 | 262.24 | 256.08 | 234.54 | 170.85 | |
| Receivables Turnover | 1,062.90 | 1,144.31 | 770.27 | 1,066.00 | 1,417.23 | 795.15 | 581.14 | 846.51 | 884.56 | 743.88 | 657.10 | 700.93 | 666.29 | 619.24 | 629.33 | |
| Payables Turnover | 38.40 | 35.51 | 107.86 | 276.32 | 264.11 | 85.66 | 167.52 | 342.48 | 371.81 | 369.00 | 625.22 | 474.61 | 463.69 | 355.48 | 345.90 | |
|
Asset Turnover
|
5.22 | 8.31 | 63.99 | 55.34 | 52.26 | 24.84 | 41.34 | 58.82 | 70.18 | 48.79 | 50.04 | 52.81 | 56.39 | 49.20 | 43.29 | |
| Fixed Turnover | 163.86 | 198.21 | 1,059.22 | 352.17 | 173.91 | 81.08 | 147.96 | 243.74 | 315.24 | 375.32 | 558.71 | 647.41 | 692.30 | 805.73 | 677.20 | |
| Coverage | ||||||||||||||||
| Interest Coverage | -4,649.88 | -3,611.29 | 311.20 | 15.85 | -3,974.69 | -950.29 | -556.57 | 12.20 | 214.15 | 1,861.57 | 2,047.05 | 4,911.85 | 4,523.74 | 7,860.22 | 8,503.85 | |
| Asset Coverage | 500 | 100 | 200 | 200 | 400 | 200 | 200 | 300 | 400 | 900 | 1,100 | 1,600 | 2,000 | 2,700 | 2,200 | |
| Cash Flow Coverage (CFGR) | -230.00 | -118.33 | 24.14 | 39.02 | -11.26 | -59.86 | -40.26 | 20.39 | 144.08 | 220.16 | 258.26 | 521.47 | 437.96 | 736.17 | 437.57 | |
| EBITDA Coverage | -4,100 | -3,400 | 600 | - - | 2,200 | -800 | -500 | - - | 500 | 1,900 | 2,400 | 5,400 | 4,500 | 7,900 | 8,900 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | 100 | 100 | - - | - - | - - | 100 | 100 | 100 | 100 | 200 | 100 | 200 | 100 | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -8.64 | -10.75 | 0.44 | -1.21 | -2.66 | -2.65 | -1.84 | -0.62 | 0.71 | 4.98 | 2.09 | 4.42 | 4.14 | 4.49 | 3.45 | |
|
Price/Earnings (P/E)
|
-1,157.17 | -930.27 | 23,008.15 | -8,297.09 | -3,753.69 | -3,778.77 | -5,429.80 | -16,015.22 | 14,154.13 | 2,009.58 | 4,776.52 | 2,264.66 | 2,416.25 | 2,226.27 | 2,896.88 | |
| Price/Earnings Growth (PEG) | -88.00 | -491.72 | -221.84 | 18.15 | -12.68 | -64.50 | 205.42 | 199.97 | -42.83 | 2.96 | -107.37 | 17.70 | -186.86 | 52.16 | 347.89 | |
|
Price/Book (P/B)
|
676.80 | 1,392.95 | 864.78 | 888.78 | 1,231.56 | 2,545.95 | 2,773.41 | 1,341.02 | 1,826.07 | 950.10 | 923.72 | 706.94 | 560.31 | 531.58 | 596.43 | |
| Price/Tangible Book (P/TB) | 676.80 | 1,392.95 | 864.78 | 888.78 | 1,231.56 | 2,545.95 | 2,773.41 | 1,341.02 | 1,826.07 | 950.10 | 923.72 | 706.94 | 560.31 | 531.58 | 596.43 | |
| Price/Sales (P/S) | 7,275.08 | 4,896.48 | 482.37 | 581.55 | 1,378.33 | 4,808.33 | 2,935.53 | 1,054.26 | 1,498.56 | 1,382.69 | 1,350.30 | 989.59 | 747.13 | 828.12 | 1,065.71 | |
|
Price/Cash Flow (P/CF)
|
-1,736.29 | -1,104.76 | 4,734.01 | 3,315.60 | -32,392.79 | -5,438.10 | -8,292.80 | 7,600.65 | 4,413.78 | 3,317.26 | 3,581.82 | 1,887.53 | 2,140.76 | 1,790.76 | 2,964.28 | |
| Price/Free CF (P/FCF) | -1,645.85 | -1,042.33 | 13,847.03 | 4,514.74 | -16,224.24 | -4,944.77 | -7,378.14 | 9,995.19 | 6,369.35 | 3,587.00 | 3,762.73 | 2,051.33 | 2,349.63 | 1,884.15 | 3,197.89 | |
| Price/Operating CF (P/OCF) | -1,736.29 | -1,104.76 | 4,734.01 | 3,315.60 | -32,392.79 | -5,438.10 | -8,292.80 | 7,600.65 | 4,413.78 | 3,317.26 | 3,581.82 | 1,887.53 | 2,140.76 | 1,790.76 | 2,964.28 |